Results 131 to 140 of about 2,936,436 (245)

Living at genetic risk: The patient experience of Lynch syndrome

International Journal of Cancer, EarlyView.
Abstract Lynch syndrome is a germline cancer predisposition syndrome caused by a variant in one of four genes. Lynch syndrome places individuals at significantly higher risk for a range of cancers, especially colorectal and endometrial. Depending on which gene is affected, the risk of ovarian, gastric, small bowel, pancreatic, biliary urothelial, brain,
Nicola Reents, Georgina Hoffmann, Kelly Kohut   +2 more
wiley   +1 more source

Clinical Implementation and Oncological Relevance of Molecular Profiling in Brain Metastases Patients—A Multicenter Retrospective Cohort Study

International Journal of Cancer, EarlyView.
While current guidelines recommend the analysis of established cancer driver genes in brain metastases, little is known about its real‐life implementation. This multicenter study revealed an upward trend in the profiling rates of surgically treated brain metastases over the past decade, with up to 60% of brain metastases samples undergoing analysis ...
Maria Nikolaeva, Jacopo Bellomo, Meltem Gönel, Vittorio Stumpo, Victor Egon Staartjes, Flavio Vasella, Kevin Akeret, André Sagerer, Anna Maria Zeitlberger, David Wasilewski, Christopher Krämer, Sven König, Julia Onken, Tareq Juratli, Alexander Köpp, Regina Reimann, Marcus Czabanka, Peter Vajkoczy, Ilker Y. Eyüpoglu, Oliver Bozinov, Michael Weller, Emilie Le Rhun, Luca Regli, Carlo Serra, Marian C. Neidert, Stefanos Voglis   +25 more
wiley   +1 more source

De‐Escalation of Neoadjuvant Treatment for HER2‐Positive Breast Cancer

International Journal of Cancer, EarlyView.
ABSTRACT With improved prognosis in early HER2‐positive breast cancer, safely de‐escalating treatment is increasingly investigated to minimize overtreatment. This article focuses on neoadjuvant de‐escalation strategies for HER2‐positive breast cancer.
Yiyin Ma, Dedian Chen, Sheng Huang
wiley   +1 more source

Assessment of Cancer‐Related Cognitive Impairments Across Anti‐Cancer Therapies in a Predominantly Breast Cancer Cohort

International Journal of Cancer, EarlyView.
ABSTRACT Cancer survivors frequently experience cancer‐related cognitive impairment (CRCI), but the contributions of different anti‐cancer therapies remain unclear. Patients with breast or gynaecological cancer were recruited before any anti‐cancer treatment.
Qiqi Lei, Martina E. Schmidt, Philipp Zimmer, Patric Meyer, Andreas Schneeweiss, Karen Steindorf   +5 more
wiley   +1 more source

Epilepsy surgery through a reproductive lifespan lens

Epilepsia, EarlyView.
Aisha A. Abdulrazaq, Dorothee Kasteleijn‐Nolst Trenite, Torbjörn Tomson   +2 more
wiley   +1 more source

Second Breast‐Conserving Treatment for Ipsilateral Breast Tumor Recurrence: A Review of Patient Selection, Reirradiation Techniques, and Clinical Outcomes

International Journal of Cancer, EarlyView.
ABSTRACT Local recurrence after primary breast cancer treatment remains a complex clinical scenario in patients previously treated with breast‐conserving therapy and radiotherapy. For decades, salvage mastectomy was considered the standard treatment for ipsilateral breast tumor recurrence, largely because of concerns about local control after repeat ...
Cezara Cheptea, Youlia Kirova, Radu Iulian Mitrica, Mihaela Badea, Pierre Loap   +4 more
wiley   +1 more source

Estimation of Subtype‐Specific Tumour Growth Rate Distributions and Interval Cancer Proportions in Breast Cancer Using Biology‐Inspired Natural History Models

International Journal of Cancer, EarlyView.
ABSTRACT Breast cancer progression varies across molecular subtypes, influencing detection rates and prognosis. Differences in the proportion of interval cancers (PIC)—cancers detected symptomatically between scheduled screening rounds—have been observed across subtypes, likely reflecting heterogeneity in tumour growth dynamics. We applied a continuous‐
Letizia Orsini, Yuqi Zhang, Kamila Czene, Keith Humphreys   +3 more
wiley   +1 more source

Trends in estrogen replacement therapy use among younger gynecologic cancer survivors, 2013-2021. [PDF]

Gynecol Oncol Rep
Wang CH, Shan Y, Richardson G, Guo F, Adekanmbi V, Hoang TN, Berenson AB.   +6 more
europepmc   +1 more source

Tibolone Use Associated With Elevated Hepatocellular Carcinoma Risk: Findings From a Nationwide Cohort

International Journal of Cancer, EarlyView.
ABSTRACT Tibolone, a synthetic steroid with estrogenic, progestogenic, and androgenic activity, is widely prescribed for menopausal symptoms, but its association with hepatocellular carcinoma (HCC) remains unclear. Using data from 117,271 women aged ≥ 45 years in the Korean National Health Insurance Service–Health Screening Cohort, we evaluated ...
Jimin Lee, Hye Jun Kim, Sun Jae Park, Sangwoo Park, Jina Chung, Jiwon Yu, Ju Hyun Kang, Seogsong Jeong, Hyun‐Young Shin, Sang Min Park   +9 more
wiley   +1 more source

Estrogen Replacement Therapy in Ovariectomized Rats: Complementary Roles of ER and GPR30 in Alleviating Depressive-like Behavior. [PDF]

Curr Issues Mol Biol
He S, Ren Z, Wu L, Xie Y, Sun L, Xiao L, Wang G.   +6 more
europepmc   +1 more source